- Home
- TLRY vs BWAY Comparison
TLRY vs BWAY Comparison
Compare TLRY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Canada | Israel |
| Employees | N/A | 129 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.4M | 578.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLRY | BWAY |
|---|---|---|
| Price | $3.91 | $16.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $72.33 | $13.25 |
| AVG Volume (30 Days) | ★ 3.5M | 99.2K |
| Earning Date | 04-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.79 | $309.69 |
| Revenue Next Year | $19.98 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $11.35 |
| 52 Week High | $15.70 | $26.63 |
Technical Indicators
Market Signals| Indicator | TLRY | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 54.99 |
| Support Level | $0.77 | $14.21 |
| Resistance Level | $4.85 | $16.34 |
| Average True Range (ATR) | 0.18 | 0.77 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 3.18 | 59.04 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.